Immediate hypersensitivity to human recombinant granulocyte-macrophage colony-stimulating factor associated with a positive prick skin test reaction

Annals of Allergy, Asthma and Immunology

Volumn 76, Issue 6, 1996, Pages 531-534

  Engler, Renata J M ^a   Weiss, Raymond B ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; HISTAMINE; HUMAN SERUM ALBUMIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SODIUM CHLORIDE;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; NEURILEMOMA; PRICK TEST; PRIORITY JOURNAL; PRURITUS; SKIN TEST; SUBCUTANEOUS DRUG ADMINISTRATION; URTICARIA;

EID: 0029889223     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63273-5     Document Type: Article

References (20)

1. Metcalf D. The colony-stimulating factors: discovery, development, and clinical applications. Cancer 1990;65: 2185-95.
2. Hermann F, Schulz G, Wieser M, et al. Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. Am J Med 1990;88:619-24.
3. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, et al. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol 1992; 10:1266-77.
4. Thompson JA, Lee DJ, Kidd P, et al. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematologic effects. J Clin Oncol 1989;7: 629-37.
5. Levine JD, Allan JD, Tessitor JH, et al. Granulocyte-macrophage colony stimulating factor ameliorates the neutropenia induced by azidothymidine in AIDS/ARC patients. Proc Am Soc Clin Oncol 1989;8:1(#3).
6. Weisbart RH, Gasson JC, Golde DW. Colony-stimulating factors and host defense. Ann Intern Med 1989;110: 297-303.
7. Lopez AF, Williamson J, Gamble JP, et al. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature neutrophils and eosinophil functions, surface receptor expression and survival. J Clin Invest 1986;78:1220-8.
8. Arnaout MA, Wang EA, Clark SC, Sieff CA. Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest 1986;78:597-601.
9. Gribben JG, Devereaux S, Thomas NSB, et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 1990;335:434-7.
10. Moonen P, Mermod JJ, Ernst JF, et al. Increased biological activity of deglycosolated recombinant human granulocyte-macrophage colony-stimulating factor produced by yeast or animal cells. Proc Natl Acad Sci USA 1987; 84:4428-31.
11. Dorr RT. Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor. Clin Therapeutics 1993;15:19-29.
12. Antonelli G, Currenti M, Turriziani G, Dianzani F. Neutralizing antibodies to interferon-α: Relative frequency in patients treated different interferon preparations. J Infect Dis 1991;16:882-5.
13. Spiegel RJ, Spicehandler JR, Jacobs SI, Oden EM. Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A). Am J Med 1986;80:223-8.
14. O'Shaughnessy JA, Denicoff AM, Venzon DJ, et al. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients. Ann Oncology 1994;5:709-16.
15. Bokemeyer C, Schmoll HJ, Metzner B, et al. Comparison of 5 vs 10 meg/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer. Ann Hematol 1993;67(2):75-9.
16. Ackland SP, Hillcoat BL. Immediate hypersensitivity to mannitol: a potential cause of apparent hypersensitivity to cisplatin. Cancer Treatment Rep 1985;5:562-3.
17. Spaeth GL, Spaeth EB, Spaeth PG, Lucier AC. Anaphylactic reaction to mannitol. Arch Ophthal 1967;78: 583-4.
18. Jaiyesimi I, Giralt SS, Wood J. Subcutaneous granulocyte colony-stimulating factor and acute anaphylaxis. N Engl J Med 1991;325:587. (Reply by Amgen included)
19. Locker GJ, Simonitsch I, Mader RM, et al. Cutaneous effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: Immune phenomena or drug toxicity? Breast Cancer Res Treatment 1995;34: 213-9.
20. Horn TD, Burke PJ, Karp JE, Hood AF. Intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor causes a cutaneous eruption. Arch Dermatol 1991;127:49-52.